A Phase 3 interventional study of Secutrelvir and Placebo in COVID-19, sponsored by Shionogi. Recruiting at 1 site in Japan. Open to participants aged 12 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in COVID-19 with a site in Japan — 10 open to participants now, 11 under way, 8 of them phase 3. COVID-19 · Japan.
Among the 75 studies in COVID-19 with a site in Japan, this one is the 21st largest by planned enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2026, is one of 34 in phase 3, reaches primary completion later than 4 of the 10 other live ones, and was the 73rd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →10 of the 75 studies in COVID-19 with a site in Japan are open now. Recruiting first, the newest first:
Shionogi · Sites in Japan, United States, Bulgaria
Ages 12+
Pfizer · Sites in Japan, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Japan, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Japan, United States, Argentina and 21 more countries
Ages 18+
AstraZeneca · Sites in Japan, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 19 · Phase 3 40 · Phase 4 1
First in 2016; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 602 across the 59 interventional studies, 3,346 across the 15 observational. Of the 58 that completed or were terminated, 36 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 75 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 7 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
5 of the studies in COVID-19 with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07746544Phase 3ShionogiStudy of Secutrelvir in Participants With COVID-19 | 2027-07-31 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07739446Chiba UniversityEffect of Surgical Masks in Preventing Acute Respiratory Infections | 2027-03 |
Add all 5 to your calendar (.ics) → With an account.
Among the 75 studies in COVID-19 with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive secutrelvir administered orally.
Drug: Secutrelvir
Participants will receive placebo administered orally.
Drug: Placebo
Secutrelvir will be administered orally as a tablet.
Also known as: S-892216
Placebo will be administered orally as a tablet.
Time to First Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Time to Sustained Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 28
Time to Sustained Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Time to First Resolution of 14 Protocol-defined Symptoms of COVID-19 Symptoms Through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 28
Time to First Alleviation of 14 Protocol-defined Symptoms of COVID-19 Through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Time to Sustained Alleviation of 14 Protocol-defined Symptoms of COVID-19 Through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Area Under The Curve (AUC) of Change From Baseline in Protocol-defined 14 COVID 19 Symptoms Total Score at Day 8
Time frame: Baseline, Day 8
Time to First Resolution of Fever Based on Body Temperature
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 28
Time to Sustained Resolution of Fever Based on Body Temperature
Symptoms will be assessed by the investigator via a participant daily electronic diary
Time frame: Baseline through Day 28
Change From Baseline in SARS-CoV-2 Viral RNA Level
Time frame: Baseline through Day 28
Percentage of Participants With All-cause Hospitalization
Time frame: Baseline through Day 21
Percentage of Participants With All-cause Death
Time frame: Baseline through Day 21
Plasma Concentration of Secutrelvir and Its Metabolites
Time frame: Days 4 and 8
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline through Day 28
Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 11 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.